News

Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Nasdaq20d
Novo Nordisk Expands $499 Wegovy Savings Offer To All Cash-paying Patients
(RTTNews) - Novo Nordisk (NVO) has expanded its $499 per month Wegovy savings program to include all cash-paying patients. Till now, the reduced price offer was only available with NovoCare pharmacy.
Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)
In its fourth quarter 2024 investor letter, Artisan Global Opportunities Fund emphasized stocks such as Novo Nordisk A/S ...
Morningstar20d
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Until today, the $499-per-month offer for Wegovy® was only available via the recently launched NovoCare® Pharmacy. "At Novo Nordisk, we are committed to developing innovative medicines and will ...
Insider Monkey25d
Novo Nordisk A/S (NVO) Traded Lower Due To Investor Disappointment Over Its New Drug In Obesity
In its fourth quarter 2024 investor letter, Burke Wealth Management emphasized stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and development ...
Longview News-Journal20d
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
The Wegovy ® savings offer is good for all dose strengths of Wegovy ® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choice "At Novo Nordisk, we are ...